Table 2.

Dosing, How Supplied, and Dose Adjustments for PARP Inhibitors

Generic (Brand)	Niraparib (Zejula)	Olaparib (Lynparza)	Rucaparib (Rubraca)
Manufacturer	Tesaro	AstraZeneca	Clovis Oncology
Initial Dosing	300 mg orally once daily	Capsules: 400 mg orally twice daily Tablets: 300 mg orally twice daily	600 mg orally twice daily
How Supplied	Capsules: 100 mg	Capsules: 50 mg Tablets: 100 mg, 150 mg Do not substitute capsules for tablets on a mg-per-mg basis	Tablets: 200 mg, 250 mg, 300 mg
Renal Impairment	CrCl 30–90 mL/min: No adjustment suggested CrCl < 30 mL/min: Not studied ESRD: Not studied	CrCl 51–80 mL/min: No adjustment suggested CrCl 31–50 mL/min: Capsules: Reduce to 300 mg twice daily Tablets: Reduce to 200 mg twice daily CrCl < 30 mL/min: Not studied ESRD: Not studied	CrCl > 30 mL/min: No adjustment suggested CrCl < 30 mL/min: Not studied ESRD: Not studied
Hepatic Impairment	Mild (Child-Pugh Class A): No adjustment suggested Moderate to severe (Child-Pugh classes B and C): Not studied	Mild (Child-Pugh Class A): No adjustment suggested Moderate to severe (Child-Pugh classes B and C): Not studied	Mild (Child-Pugh Class A): No adjustment suggested Moderate to severe (Child-Pugh classes B and C): Not studied
Dose Adjustment for Toxicity	First dose reduction: 200 mg daily Second dose reduction: 100 mg daily	Capsules: First dose reduction: 200 mg twice daily Second dose reduction: 100 mg twice daily Tablets: First dose reduction: 250 mg twice daily Second dose reduction: 200 mg twice daily	First dose reduction: 500 mg twice daily Second dose reduction: 400 mg twice daily Third dose reduction: 300 mg twice daily

CrCl = creatinine clearance; ESRD = end-stage renal disease.